Current practice of antifungal prophylaxis and treatment in immunocompromised children and adults with malignancies: a single centre approach.
Although various guidelines on antifungal prophylaxis and treatment have been published, the practical approach in the individual clinical setting might considerably differ because of special local circumstances. In addition, there are major differences between paediatric and adult patients regarding antifungal strategies and the use of antifungal compounds. We here present the antifungal approach in the Departments of Hematology and Oncology of the University Hospital of Frankfurt, where per year approximately 350 children and adults are diagnosed with cancer and an additional 100 patients undergo haematopoietic stem cell transplantation. The differences in the approach between the paediatric and adult setting are highlighted.
Lehrnbecher
Thomas
T
Pediatric Hematology and Oncology, Children's University Hospital, Johann Wolfgang Goethe University, Frankfurt am Main, Germany. thomas.lehrnbecher@kgu.de
Mousset
Sabine
S
Sörensen
Jan
J
Böhme
Angelika
A
D000328:Adult; D000367:Age Factors; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018890:Chemoprevention; D002648:Child; D005858:Germany; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006785:Hospitals, University; D006801:Humans; D016867:Immunocompromised Host; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control*; D009369:Neoplasms / Q000628:therapy*; D010372:Pediatrics; D016032:Randomized Controlled Trials as Topic; D014182:Transplantation, Autologous / Q000009:adverse effects*
D000935:Antifungal Agents